Immatics, Roche ally to trial Tecentriq with cell therapy
Immatics has struck a deal to test its autolog | Immatics has struck a deal to test its autologous cell therapy in combination with Roche’s checkpoint inhibitor Tecentriq. The clinical collaboration clears Immatics to test whether Roche’s antibody boosts the efficacy of its IMA101 in solid tumors.www.fiercebiotech.com